PMC:7324763 / 58910-59755 JSONTXT

{"project":"LitCovid-PMC-OGER-BB","denotations":[{"id":"T932","span":{"begin":24,"end":29},"obj":"PR:000001373"},{"id":"T933","span":{"begin":89,"end":94},"obj":"PR:000001373"},{"id":"T934","span":{"begin":121,"end":126},"obj":"PR:000001373"},{"id":"T935","span":{"begin":220,"end":225},"obj":"PR:000001373"},{"id":"T936","span":{"begin":265,"end":270},"obj":"PR:000001373"},{"id":"T937","span":{"begin":329,"end":337},"obj":"SP_7"},{"id":"T938","span":{"begin":348,"end":353},"obj":"PR:000001373"},{"id":"T939","span":{"begin":377,"end":380},"obj":"PR:000023847"},{"id":"T940","span":{"begin":398,"end":404},"obj":"NCBITaxon:9606"},{"id":"T941","span":{"begin":563,"end":573},"obj":"GO:0000075"},{"id":"T942","span":{"begin":574,"end":584},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T943","span":{"begin":728,"end":736},"obj":"CL:0000623"},{"id":"T88350","span":{"begin":24,"end":29},"obj":"PR:000001373"},{"id":"T43303","span":{"begin":89,"end":94},"obj":"PR:000001373"},{"id":"T78067","span":{"begin":121,"end":126},"obj":"PR:000001373"},{"id":"T19413","span":{"begin":220,"end":225},"obj":"PR:000001373"},{"id":"T12514","span":{"begin":265,"end":270},"obj":"PR:000001373"},{"id":"T37844","span":{"begin":329,"end":337},"obj":"SP_7"},{"id":"T12024","span":{"begin":348,"end":353},"obj":"PR:000001373"},{"id":"T21289","span":{"begin":377,"end":380},"obj":"PR:000023847"},{"id":"T81107","span":{"begin":398,"end":404},"obj":"NCBITaxon:9606"},{"id":"T33457","span":{"begin":563,"end":573},"obj":"GO:0000075"},{"id":"T57505","span":{"begin":574,"end":584},"obj":"CHEBI:35222;CHEBI:35222"},{"id":"T94885","span":{"begin":728,"end":736},"obj":"CL:0000623"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T738","span":{"begin":24,"end":26},"obj":"Body_part"},{"id":"T739","span":{"begin":44,"end":51},"obj":"Body_part"},{"id":"T740","span":{"begin":47,"end":51},"obj":"Body_part"},{"id":"T741","span":{"begin":89,"end":91},"obj":"Body_part"},{"id":"T742","span":{"begin":121,"end":123},"obj":"Body_part"},{"id":"T743","span":{"begin":127,"end":129},"obj":"Body_part"},{"id":"T744","span":{"begin":220,"end":222},"obj":"Body_part"},{"id":"T745","span":{"begin":265,"end":267},"obj":"Body_part"},{"id":"T746","span":{"begin":348,"end":350},"obj":"Body_part"},{"id":"T747","span":{"begin":518,"end":525},"obj":"Body_part"},{"id":"T748","span":{"begin":521,"end":525},"obj":"Body_part"},{"id":"T749","span":{"begin":544,"end":551},"obj":"Body_part"},{"id":"T750","span":{"begin":547,"end":551},"obj":"Body_part"},{"id":"T751","span":{"begin":685,"end":693},"obj":"Body_part"},{"id":"T752","span":{"begin":728,"end":736},"obj":"Body_part"},{"id":"T753","span":{"begin":731,"end":736},"obj":"Body_part"},{"id":"T754","span":{"begin":760,"end":768},"obj":"Body_part"}],"attributes":[{"id":"A738","pred":"fma_id","subj":"T738","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A739","pred":"fma_id","subj":"T739","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A740","pred":"fma_id","subj":"T740","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A741","pred":"fma_id","subj":"T741","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A742","pred":"fma_id","subj":"T742","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A743","pred":"fma_id","subj":"T743","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A744","pred":"fma_id","subj":"T744","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A745","pred":"fma_id","subj":"T745","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A746","pred":"fma_id","subj":"T746","obj":"http://purl.org/sig/ont/fma/fma86578"},{"id":"A747","pred":"fma_id","subj":"T747","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A748","pred":"fma_id","subj":"T748","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A749","pred":"fma_id","subj":"T749","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A750","pred":"fma_id","subj":"T750","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A751","pred":"fma_id","subj":"T751","obj":"http://purl.org/sig/ont/fma/fma84050"},{"id":"A752","pred":"fma_id","subj":"T752","obj":"http://purl.org/sig/ont/fma/fma63147"},{"id":"A753","pred":"fma_id","subj":"T753","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A754","pred":"fma_id","subj":"T754","obj":"http://purl.org/sig/ont/fma/fma84050"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T429","span":{"begin":329,"end":337},"obj":"Disease"},{"id":"T430","span":{"begin":609,"end":615},"obj":"Disease"},{"id":"T431","span":{"begin":810,"end":813},"obj":"Disease"}],"attributes":[{"id":"A429","pred":"mondo_id","subj":"T429","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A430","pred":"mondo_id","subj":"T430","obj":"http://purl.obolibrary.org/obo/MONDO_0004992"},{"id":"A431","pred":"mondo_id","subj":"T431","obj":"http://purl.obolibrary.org/obo/MONDO_0007399"},{"id":"A432","pred":"mondo_id","subj":"T431","obj":"http://purl.obolibrary.org/obo/MONDO_0017361"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T746","span":{"begin":30,"end":39},"obj":"http://purl.obolibrary.org/obo/SO_0000418"},{"id":"T747","span":{"begin":44,"end":51},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T748","span":{"begin":398,"end":404},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T749","span":{"begin":514,"end":517},"obj":"http://purl.obolibrary.org/obo/CLO_0002199"},{"id":"T750","span":{"begin":518,"end":525},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T751","span":{"begin":544,"end":551},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T752","span":{"begin":728,"end":736},"obj":"http://purl.obolibrary.org/obo/CL_0000623"},{"id":"T753","span":{"begin":777,"end":780},"obj":"http://purl.obolibrary.org/obo/CLO_0051582"},{"id":"T754","span":{"begin":781,"end":782},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T39","span":{"begin":24,"end":26},"obj":"Chemical"},{"id":"T97824","span":{"begin":89,"end":91},"obj":"Chemical"},{"id":"T43","span":{"begin":121,"end":123},"obj":"Chemical"},{"id":"T45","span":{"begin":127,"end":129},"obj":"Chemical"},{"id":"T5691","span":{"begin":220,"end":222},"obj":"Chemical"},{"id":"T49","span":{"begin":265,"end":267},"obj":"Chemical"},{"id":"T66378","span":{"begin":348,"end":350},"obj":"Chemical"},{"id":"T53","span":{"begin":574,"end":584},"obj":"Chemical"},{"id":"T93921","span":{"begin":594,"end":597},"obj":"Chemical"}],"attributes":[{"id":"A48463","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A82998","pred":"chebi_id","subj":"T39","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A28543","pred":"chebi_id","subj":"T97824","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A24446","pred":"chebi_id","subj":"T97824","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A10184","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A85831","pred":"chebi_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A60612","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A56988","pred":"chebi_id","subj":"T45","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A99911","pred":"chebi_id","subj":"T5691","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A10098","pred":"chebi_id","subj":"T5691","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A44909","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A62666","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A62065","pred":"chebi_id","subj":"T66378","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A37605","pred":"chebi_id","subj":"T66378","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A75631","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A41196","pred":"chebi_id","subj":"T93921","obj":"http://purl.obolibrary.org/obo/CHEBI_41001"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1671","span":{"begin":24,"end":29},"obj":"Gene"},{"id":"1672","span":{"begin":89,"end":94},"obj":"Gene"},{"id":"1673","span":{"begin":121,"end":126},"obj":"Gene"},{"id":"1674","span":{"begin":220,"end":225},"obj":"Gene"},{"id":"1675","span":{"begin":265,"end":270},"obj":"Gene"},{"id":"1676","span":{"begin":348,"end":353},"obj":"Gene"},{"id":"1677","span":{"begin":514,"end":517},"obj":"Gene"},{"id":"1678","span":{"begin":338,"end":346},"obj":"Species"},{"id":"1679","span":{"begin":398,"end":404},"obj":"Species"},{"id":"1680","span":{"begin":329,"end":337},"obj":"Disease"},{"id":"1681","span":{"begin":609,"end":615},"obj":"Disease"}],"attributes":[{"id":"A1671","pred":"tao:has_database_id","subj":"1671","obj":"Gene:3600"},{"id":"A1672","pred":"tao:has_database_id","subj":"1672","obj":"Gene:3600"},{"id":"A1673","pred":"tao:has_database_id","subj":"1673","obj":"Gene:3600"},{"id":"A1674","pred":"tao:has_database_id","subj":"1674","obj":"Gene:3600"},{"id":"A1675","pred":"tao:has_database_id","subj":"1675","obj":"Gene:3600"},{"id":"A1676","pred":"tao:has_database_id","subj":"1676","obj":"Gene:3600"},{"id":"A1677","pred":"tao:has_database_id","subj":"1677","obj":"Gene:653108"},{"id":"A1678","pred":"tao:has_database_id","subj":"1678","obj":"Tax:9606"},{"id":"A1679","pred":"tao:has_database_id","subj":"1679","obj":"Tax:9606"},{"id":"A1680","pred":"tao:has_database_id","subj":"1680","obj":"MESH:C000657245"},{"id":"A1681","pred":"tao:has_database_id","subj":"1681","obj":"MESH:D009369"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T87","span":{"begin":609,"end":615},"obj":"Phenotype"}],"attributes":[{"id":"A87","pred":"hp_id","subj":"T87","obj":"http://purl.obolibrary.org/obo/HP_0002664"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T143","span":{"begin":30,"end":39},"obj":"http://purl.obolibrary.org/obo/GO_0023052"},{"id":"T144","span":{"begin":127,"end":133},"obj":"http://purl.obolibrary.org/obo/GO_0042010"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"MyTest","denotations":[{"id":"32655581-25833053-34771778","span":{"begin":227,"end":230},"obj":"25833053"},{"id":"32655581-29628312-34771779","span":{"begin":406,"end":409},"obj":"29628312"},{"id":"32655581-28823521-34771780","span":{"begin":617,"end":620},"obj":"28823521"}],"namespaces":[{"prefix":"_base","uri":"https://www.uniprot.org/uniprot/testbase"},{"prefix":"UniProtKB","uri":"https://www.uniprot.org/uniprot/"},{"prefix":"uniprot","uri":"https://www.uniprot.org/uniprotkb/"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"TEST0","denotations":[{"id":"32655581-227-234-3171351","span":{"begin":227,"end":230},"obj":"[\"25833053\"]"},{"id":"32655581-173-180-3171352","span":{"begin":406,"end":409},"obj":"[\"29628312\"]"},{"id":"32655581-231-238-3171353","span":{"begin":617,"end":620},"obj":"[\"28823521\"]"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"2_test","denotations":[{"id":"32655581-25833053-34771778","span":{"begin":227,"end":230},"obj":"25833053"},{"id":"32655581-29628312-34771779","span":{"begin":406,"end":409},"obj":"29628312"},{"id":"32655581-28823521-34771780","span":{"begin":617,"end":620},"obj":"28823521"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}

{"project":"LitCovid-sentences","denotations":[{"id":"T361","span":{"begin":0,"end":232},"obj":"Sentence"},{"id":"T362","span":{"begin":233,"end":622},"obj":"Sentence"},{"id":"T363","span":{"begin":623,"end":845},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Given the importance of IL-15 signaling and NK cell function, researchers have developed IL-15 “superagonists” which are IL-15:IL-15R heterodimers that have better in vivo stability and bioactivity compared to monomeric IL-15 (168). Although at the time of writing IL-15 superagonists are not being studied for their efficacy in COVID-19 patients, IL-15 superagonists, such as ALT-803, are safe in humans (188) and have been used in conjunction with many of the therapies being discussed in this review including: CAR-NK cell therapy, adoptive NK cell transfers, checkpoint inhibitors, and the BCG vaccine in cancer (189). It should be noted that although the therapeutic potential of cytokine therapy to specifically stimulate NK cells is enticing, exogenous cytokine therapy has a high risk for exacerbating CRS if given at the incorrect time."}